



RAPID

Contact:
Peter Evers
Natron Communications
(415) 524-8899
peter@natroncomm.com

iSchemaView's RAPID™ Adopted by More Than 700 Stroke Centers — Over 100 Percent Growth This Year

*More Than 2,000 Cases Weekly on RAPID's Advanced Imaging Platform,
the Imaging Standard for Stroke Centers*

Redwood City, Calif. — October 29, 2018 — Today, on World Stroke Day, iSchemaView, the worldwide leader in advanced imaging for stroke, announced that adoption of its RAPID advanced imaging platform has grown more than 100 percent year-to-date. Over 700 stroke centers around the world have now contracted to use the RAPID platform commercially, and over 300 sites are installing RAPID for clinical research, including multinational trials.

“On a day dedicated to stroke awareness, we are proud to play a growing role in helping stroke patients globally,” said Don Listwin, CEO of iSchemaView. “With stroke centers now delivering over 100,000 RAPID cases a year, dramatically more patients are receiving treatment than ever before.”

RAPID has quickly become the ubiquitous standard in the analysis of brain images using automated tools for CT ASPECTS, CT angiography, CT perfusion and MR diffusion and perfusion. Developed by leading stroke experts, RAPID combines unmatched expert feature extraction, proprietary algorithms and machine learning to deliver the best-in-class platform, one that has quickly become the standard in three quarters of U.S. comprehensive stroke centers.

“This is an amazing moment in stroke medicine, and with the backdrop of World Stroke Day, it is the ideal time to celebrate the landmark research that has recently opened new treatment windows for so many more patients,” said Dr. Greg Albers, Professor of

Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of iSchemaView. “We are incredibly gratified that the RAPID platform, built on clinical data and deep stroke expertise, is helping researchers drive this transformation in the treatment of stroke.”

RAPID, the worldwide imaging platform of choice for stroke research, was chosen as the imaging solution for patient selection in five groundbreaking clinical trials. These include SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and, most recently, EXTEND. In addition to transforming selection for thrombectomy procedures, the positive results of the EXTEND trial that were recently presented at the World Stroke Congress, demonstrate that RAPID may now allow primary stroke centers to potentially provide effective treatment for patients who present beyond the traditional time window for intravenous tPA therapy.

“I would like to congratulate the EXTEND investigators for this landmark achievement,” continued Dr. Albers. “For the last two decades, numerous investigators have attempted to expand the window for intravenous tPA therapy. The results of the EXTEND study will dramatically increase the number of patients who can benefit from intravenous thrombolysis.”

Under IRB approval, the RAPID platform was also used to select patients for two landmark stroke trials published in *The New England Journal of Medicine*, DAWN and DEFUSE 3, that successfully treated patients up to twenty-four hours after onset. RAPID was the exclusive imaging tool used to aid in patient selection in both studies. The results of the studies helped change the American Heart Association and American Stroke Association’s stroke guidelines to include CT perfusion and MR perfusion.

The prior treatment window for mechanical thrombectomy was up to six hours. Starting in 2018, select patients with salvageable brain tissue identified through advanced imaging are now eligible for treatment up to twenty-four hours after they were last seen well.

About iSchemaView

iSchemaView is the worldwide leader in advanced imaging for stroke. Installed in over 700 hospitals and stroke centers, iSchemaView’s RAPID (automated CTP, MR, CTA and ASPECTS) is the most advanced stroke imaging platform. In clinical trials, under IRB, RAPID has been shown to aid in the selection of patients in early- and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND. In addition to achieving the best clinical outcomes and largest treatment effects ever obtained, these landmark studies led to new American Heart Association

and American Stroke Association guidelines and have dramatically altered the management of acute stroke around the world. For more information, visit www.iRAPID.com.

###